Reporting from ESMO 2019 Congress, Martin Reck comments on the results from 2 trials studying a combination of chemotherapy and immune checkpoint inhibitor in the first-line treatment of patients with extensive stage small cell lung cancer (SCLC), and a trial studying anlotinib in heavily pretreated patients with relapsed SCLC. He explains that after decades of research there are moderately positive results and more analysis is needed to identify meaningful biomarkers.
- 1736O: IMpower133: updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
- 1738O: Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)
- LBA89: PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN